What Cramer plunge. He has almost no impact on stock prices. His audience averages about 180K per night which is tiny. Furthermore, how many of those do you think would actually buy a $400 stock. Listen to most of the callers in, most are close to financially illiterate. Even mentioning Cramer on these boards is crazy.
Cramer has next to zero effect on the market and more specifically a $400 stock. His audience averages about 180K per night which is tiny. Of those few how many do you think would buy a $400 stock.
Interest rates in the US were pushed dramatically higher in the great inflation of the 1970's and it has taken quite a while to get them under control. Those high rates on CD's were an aberration. Up until the inflation stocks always paid more in dividends than bonds because of the risk. We have returned to that model. Utilities, oils, financials will for a long time pay higher interest than bonds and therefore bank accounts. I do not expect the 30 year Treasury to pay more than 4% for a very long time.
Celgene, $CELG, broke above a two tiered consolidation range at the end of October and ran higher to 109. It has been consolidating under resistance there since Halloween with the Bollinger bands getting tight. This is often a precursor to a move. Should it be to the upside there is a target on a Measured Move to 128.
The RSI supports a move higher, remaining in the bullish zone while the MACD is leveling after a pullback. There is resistance higher at 109.15 and then free air higher. Support lower may come at 103 and 95.85.
In a report published Friday, Bank of America analyst Ying Huang reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $418.00 to $462.00.
In the report, Bank of America noted, “We are raising our sales estimates for REGN's two late-stage pipeline products following positive Phase 2b data for dupilumab in asthma (November 11), encouraging feedback on alirocumab from physicians at the annual meeting of the American Heart Association (AHA, November 15-19), and increased confidence in the pipeline post Sanofi's analyst meeting yesterday. Our 2020 sales estimate increases to $7.0B (from $6.4B). Adjusting the probability of success for dupilumab in asthma and longer-term sales projections for alirocumab, we derive a PO of $462 (from $418) based on a probability-adjusted NPV analysis. We continue to believe that REGN has one of the most robust pipelines and see upside from current levels.”
Shares of Airgas, Inc. (ARG) reached a new 52-week high of $116.02 on Nov 18 and eventually closed at $115.79. The stock price appreciation came on the back of strong second-quarter fiscal 2015 results, expected benefits from improvement in residential construction activity and stability in mining and heavy manufacturing sectors.
The Radnor, PA-based industrial, medical and specialty gases and hardgoods supplier has a market cap of $8.7 billion and long-term expected earnings growth of 11%, suggesting good prospects for the long haul. The stock has delivered a one-year return of about 7%. Average volume of shares traded over the last three months stood at approximately 378K.
Today's news on Otezla supports your statemeny
Given the fact that the specified populations are the main targets of Otezla, we don't consider the differences to be commercially important. The timing is in line, and supports our 2015 forecast of $43m in EU sales. Given the long duration and positioning in the treatment paradigm of Otezla, we believe there is real upside to 2015-17 consensus.
Since 2017 is still two years off, lots more can happen to the entire CELG pipeline.
I see we are up almost $3 on no news that I can see. We are talking first 10 minutes of trading. All my industrials are up. Is CMI just getting sucked up with the overall market??
HOUSTON, TX--(Marketwired - November 20, 2014) - HII Technologies, Inc. (HIIT) ("HII Technologies" or the "Company"), an oilfield services company headquartered in Houston, Texas, today announced the hiring of Peter Baldwin as new Vice President of Business Development for HII Technologies' Water Divisions.
"We have been hard at work developing a comprehensive suite of oilfield services to provide to our customers and by hiring Pete, the Company will be well positioned to increase its client base and leadership position in water management and safety services," commented Brent Mulliniks, AES Water Solutions' President. "Pete's extensive industry experience and proven ability to garner strategic relationships will benefit the Company as we further execute our growth initiatives, technology commercialization and gain momentum in the market," continued Mr. Mulliniks.
Pete Baldwin has over 25 years of environmental experience with a focus on environmental, health & safety for oil and gas clients worldwide. Most recently, Mr. Baldwin was Vice President and Global Market Leader for Oil & Gas Environmental Services at CH2M HILL (the largest environmental and water engineering company in the world) with focus on groundwater, soil assessment/ remediation, oilfield water management, and safety services.
Pete Baldwin has developed environmental strategies for integrated and independent oil companies worldwide, including Shell, BP, Chevron, EOG, and Apache, and developed strategic account teams for key clients. Pete will help support development efforts by targeting new accounts and increasing awareness of HII Technologies' offerings that include Total Water Management through water transfer, storage, flow back support, recycling and evaporation; employing innovative technologies to improve quality while maintaining cost effective delivery.
TARRYTOWN, N.Y. and PARIS, Nov. 20, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are not adequately controlled with topical prescription therapy and/or for whom these treatments are not appropriate. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response. The designation is based on positive results from Phase 1 and 2 clinical trials.
"Moderate-to-severe atopic dermatitis is a debilitating, life-altering disease with very limited treatment options. Many patients suffer for years with widespread inflamed skin, intense itch, sleep disturbances and other challenges," said Julie Block, Chief Executive Officer, National Eczema Association. "We are thrilled to see the FDA recognizing the need to expedite and prioritize potential new options for these patients."
Breakthrough Therapy designation was created by the FDA to expedite the development and review of drugs that target serious or life-threatening conditions. A Breakthrough Therapy drug must show preliminary clinical evidence of a substantial improvement on a clinically significant endpoint over available therapies, or over placebo if there is no available therapy. The designation includes all of the Fast Track program features, as well as more intensive FDA guidance and discussion. The Breakthrough Therapy designation is distinct from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met.
A Phase 3 worldwide clinical program for dupilumab in adults with moderate-to-severe atopic dermatitis is ongoing.
1. If they have not split the stock by now, I doubt they will especially since almost 100% is owned by insiders or institutions. They are not going to split it for us peons.
2. The updated agreement between REGN and Sanofi pushes the 30% limit on shares they can buy out to 2020.
3. Why would the management want to sell with the current pipeline underdevelopment.
Cabot Corporation November 18, 2014 9:00 AM
Cabot Corporation (CBT) announced the launch of PURIT™ activated carbon products for sweetener applications. Cabot Norit Activated Carbon’s PURIT products deliver superior filtration, decolorization and removal of taste-affecting and odor-causing compounds from sugar syrups used in soft drinks and other beverages. This new line of multimedia products allows better filtration which enables customers to achieve significantly lower operating costs during the purification process with less environmental impact than traditional treatment methods.
The increase in soft drink consumption in developing countries has raised the need for products that can purify liquid sugar while using fewer natural resources such as electricity and water. PURIT products are dustless powder multimedia that can be used in food purification applications including liquid sugar, starch-derived sweeteners, artificial sweeteners and other liquid processes that benefit from longer cycle times due to improved filtration. Other benefits include:
Removal of turbidity, color, taste and odor in one easy step
Dust-free product decreases maintenance costs
Decreased pressure drop and extended cycle time lowers operating costs
Fewer filter changeouts reduces labor and energy costs
Increased throughput reduces cost per volume of sugar produced
“The PURIT product line represents the first multimedia activated carbon product from Cabot. These products push the boundaries of what we have come to expect from activated carbon multimedia, performing better than competitive products and striking the balance between filterability and decolorization that is so critical to performance,” said Friedrich von Gottberg, senior vice president and president Cabot Purification Solutions.
Based on current trading;
Old OXY = $86.63 (both OXY & CRC trading as one company)
New OXY = $83.06 (OXY-WI Trading)
CRC = $8.70 (CRC-WI Trading)
The two weeks prior to the split allow for these stocks to get some stability
When you think about it, KMI is an energy infrastructure company not E&P. It is primarily involved with natural gas but also oil, CO2 and chemicals and owns all types of assets like pipelines, storage, Jones vessels, wharf sites barges etc (have I missed any). It is levered more to volume than commodity prices. Since it is so cold out over a significant part of the country, we must be chewing up natural gas in particular but also heating oil. Look at natural gas futures. They have elevated substantially in the last two weeks. DEC contract is trading at $4.42 and the three winter month futures are all over $4.46. Price will stimulate extra production which can happen quickly because a lot of production is just closed in. KMI has been moving up with Natural gas prices caused by the cols weather.
I forgot, they really haven't come up with new estimates. Even though it is from a recent event they indicated that numbers will be updated. So eventually we will see a whole new estimate along with new Earnings per share.
The choppiness of refining always causes some concern among big investors, but they have beat estimates 3 of last 4 quarters and by 7.6% in total. PE based on 2014 earnings is only 12X. I think that investors forget that over 1/2 of earnings are in chemicals, midstream & specialty products which carry much higher return on invested capital. All growth investments are going into those businesses so that refining with lower margins becomes a smaller part of the business. They also do all the things I think a great stock should do. Have low debt and such huge free cash flow that they can invest for growth, pay an ever increasing dividend and opportunistically buy back shares. All these buinesses were squandered when they were run by COP.
If you do all the homework, listen to the conference calls, etc., it becomes obvious that most of the talking heads have no clue what is going on. Just look at the average mutual fund. Most managers cannot even match the market.
Following info from slide 10 - November Presentation - Credit Suisse Healthcare Conference
Expected 2017 Sales:
Revlimid $7.0 B
Total Hematology $9.5 - $10 B (apparently there is some play in the total)
Abraxane $1.5 - $2.0 B
Otazla $1.5 - $2.0 B
Total $13.0 - $14 B